I purchased some SYN for $3.92, based on the very high volume from Sep 28. There are things which I like and things which I dislike. I like that two analysts have a buy rating and Zacks Rank is a 2 - buy. I don't like that the stock fell so much since last year. I don't like the gravestone doji from yesterday. I don't like that the company is losing money. The...
SYN has a beautiful historical chart and RSI is oversold/diverging. Taking into consideration historical price action, we can see a nice rally take place here. However, a further confirmation in the form of a hammer candle on high volume is needed. Weekly chart was used for TA.
Price target is bottom of the gap 1.16, although the full gap to fill is 1.43. SYN marches towards that with momentum increasing in line with volume. At this pace, it won't be long before that gap is filled and we can look up to next target area of 1.6-1.8!
This should give us all an idea on when to buy or sell. Barring bad news from FDA
Every time it crosses the bullish trendline, it shoots back up for new highs. Every time it passes 70 on RSI, it shoots down again.
Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company's lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). Its other product candidates include SYN-007, SYN-006, SYN-005, SYN-200 and SYN-020. The Company is also developing preclinical-stage monoclonal antibody therapies for the prevention and treatment of pertussis, and discovery-stage biotherapeutics for the treatment of phenylketonuria (PKU).
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
SYN
